Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WT1 126-134 Peptide Vaccination in WT1 Expressing Carcinomas
NCT00153608Phase 2Unknown
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Apr 2004
- Modality
- Peptides, Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of WT1 126-134 peptide in carcinoma, sponsored by Charité – Universitätsmedizin Berlin. Status: unknown.
02
Drugs
WT1 126-134 peptide
03
Conditions
carcinoma
Beyond the preview
Go deeper on NCT00153608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00153608.